Zhejiang Jingxin Pharmaceutical Co Ltd (002020) - Total Liabilities
Based on the latest financial reports, Zhejiang Jingxin Pharmaceutical Co Ltd (002020) has total liabilities worth CN¥1.93 Billion CNY (≈ $281.83 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang Jingxin Pharmaceutical Co Ltd - Total Liabilities Trend (2001–2025)
This chart illustrates how Zhejiang Jingxin Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Zhejiang Jingxin Pharmaceutical Co Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Zhejiang Jingxin Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Jingxin Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Siloam International Hospitals
JK:SILO
|
Indonesia | Rp4.28 Trillion |
|
Hyundai Elevator
KO:017800
|
Korea | ₩2.70 Trillion |
|
Karooooo Ltd
NASDAQ:KARO
|
USA | $2.49 Billion |
|
Anhui Kouzi Distillery Co Ltd
SHG:603589
|
China | CN¥2.23 Billion |
|
Browave
TWO:3163
|
Taiwan | NT$887.78 Million |
|
OVH Groupe SAS
PA:OVH
|
France | €1.73 Billion |
|
Australian United Investment Company Ltd
AU:AUI
|
Australia | AU$399.22 Million |
|
Zymeworks Inc. Common Stock
NASDAQ:ZYME
|
USA | $77.20 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Zhejiang Jingxin Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Zhejiang Jingxin Pharmaceutical Co Ltd asset portfolio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Jingxin Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Jingxin Pharmaceutical Co Ltd (2001–2025)
The table below shows the annual total liabilities of Zhejiang Jingxin Pharmaceutical Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.25 Billion ≈ $329.72 Million |
-9.06% |
| 2024-12-31 | CN¥2.48 Billion ≈ $362.58 Million |
+1.28% |
| 2023-12-31 | CN¥2.45 Billion ≈ $357.99 Million |
+11.68% |
| 2022-12-31 | CN¥2.19 Billion ≈ $320.55 Million |
+38.85% |
| 2021-12-31 | CN¥1.58 Billion ≈ $230.87 Million |
-8.99% |
| 2020-12-31 | CN¥1.73 Billion ≈ $253.68 Million |
-9.44% |
| 2019-12-31 | CN¥1.91 Billion ≈ $280.13 Million |
+34.97% |
| 2018-12-31 | CN¥1.42 Billion ≈ $207.55 Million |
+51.14% |
| 2017-12-31 | CN¥938.43 Million ≈ $137.32 Million |
+8.59% |
| 2016-12-31 | CN¥864.23 Million ≈ $126.46 Million |
+27.21% |
| 2015-12-31 | CN¥679.39 Million ≈ $99.42 Million |
+1.99% |
| 2014-12-31 | CN¥666.12 Million ≈ $97.47 Million |
+31.47% |
| 2013-12-31 | CN¥506.65 Million ≈ $74.14 Million |
-4.12% |
| 2012-12-31 | CN¥528.40 Million ≈ $77.32 Million |
+23.92% |
| 2011-12-31 | CN¥426.39 Million ≈ $62.39 Million |
-32.21% |
| 2010-12-31 | CN¥629.02 Million ≈ $92.05 Million |
+3.11% |
| 2009-12-31 | CN¥610.06 Million ≈ $89.27 Million |
-6.13% |
| 2008-12-31 | CN¥649.89 Million ≈ $95.10 Million |
-9.26% |
| 2007-12-31 | CN¥716.18 Million ≈ $104.80 Million |
+49.76% |
| 2006-12-31 | CN¥478.23 Million ≈ $69.98 Million |
+71.24% |
| 2005-12-31 | CN¥279.27 Million ≈ $40.87 Million |
+54.20% |
| 2004-12-31 | CN¥181.11 Million ≈ $26.50 Million |
+6.31% |
| 2003-12-31 | CN¥170.36 Million ≈ $24.93 Million |
+42.74% |
| 2002-12-31 | CN¥119.35 Million ≈ $17.46 Million |
+6.73% |
| 2001-12-31 | CN¥111.83 Million ≈ $16.36 Million |
-- |
About Zhejiang Jingxin Pharmaceutical Co Ltd
Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China and internationally. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemi… Read more